格隆汇1月29日丨泰格医药(03347.HK)发布2025年度业绩预告。报告期内，公司营业收入为人民币66.6 亿元至人民币76.8亿元，相比上年同期上升1%–16%，重回增长态势。归属于上市公司股东的净利润为 8.3亿元至12.3亿元，相比上年同期上升105%–204%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 本 公 告 乃 由 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司「本集團」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第 13.09條 及 證 券 及 期 貨 條 例（香 港 法 例 第571章）第XIVA部項下的內幕消息 條 文（定 義 見 上 市 規 則）而 作 出。以 下 為 本 公 司 的2025年 度 業 績 預 告。本 業 績 預 告 所 載 之 財 務 數 據 未 經 審 計，本 業 績 預 告 所 載 之 財 務 數 據 根 據 中 國 企 ...

2025年，公司净新增订单(新签订单剔除取消订单后)区间为人民币95亿元至人民币105亿元，2024年同 期净新增订单为人民币84.20亿元。 泰格医药（300347）(300347.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润8.3亿 元至12.3亿元，同比增长105%–204%;归属于上市公司股东的扣除非经常性损益后的净利润3.3亿元至4.9 亿元，同比下降43%至61%。 ...

智通财经APP讯，泰格医药(300347.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 8.3亿元至12.3亿元，同比增长105%–204%;归属于上市公司股东的扣除非经常性损益后的净利润3.3亿元 至4.9亿元，同比下降43%至61%。 2025年，公司净新增订单(新签订单剔除取消订单后)区间为人民币95亿元至人民币105亿元，2024年同 期净新增订单为人民币84.20亿元。 ...

Group 1: Global Gold Demand and Market Trends - In 2025, global gold demand is projected to reach 5002 tons, marking a historical high driven by geopolitical tensions and economic uncertainties, with total demand value reaching $555 billion in the previous year [1] - On January 29, international gold prices surged, with COMEX gold reaching $5626.8 per ounce and domestic gold jewelry prices exceeding 1700 yuan per gram, reflecting a significant daily increase [1] - The high gold prices have led to a booming gold recycling market, but also to consumer risks due to inflated quotes and other malpractices in the recycling process [1] Group 2: Banking and Financial Services - By December 2025, the wealth management scale of 11 national banks reached 13.46 trillion yuan, showing a 10% increase from the beginning of the year, despite a slight decline from November [2] - The growth in wealth management is attributed to a "deposit migration" trend, with Postal Savings Bank notably rising in ranking among the banks [2] Group 3: Technology and Manufacturing - The global AMOLED smartphone panel market is expected to see a shipment of approximately 920 million units in 2025, reflecting a 4.7% year-on-year growth, driven by demand for high-end smartphones [2] - The television industry is facing challenges due to rising costs in memory, panels, and precious metals, leading to a downward adjustment in expected global shipments for 2026 [2] Group 4: Corporate Developments - Tencent has had 499 million yuan worth of shares frozen due to legal proceedings involving Linzhi Tencent Technology Co., Ltd [6] - Suzhou Lianxun Instrument Co., Ltd has received approval from the China Securities Regulatory Commission for its IPO application on the Sci-Tech Innovation Board [7] - Runxin Micro Technology has completed nearly 400 million yuan in B+ round financing, aimed at enhancing its core technology capabilities [9] Group 5: Earnings Forecasts - Bai'ao Saitou expects a net profit of 162 million to 182 million yuan in 2025, representing a year-on-year increase of 384% to 444% [13] - Nanjing Mobi expects a net profit of 24 million to 34 million yuan in 2025, indicating a growth of 269.49% to 423.44% [14] - Jinko Power anticipates a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% [15]

Core Viewpoint - Tiger Med (300347) forecasts a net profit attributable to shareholders for 2025 to be between 830 million and 1.23 billion yuan, representing a year-on-year growth of 105% to 204% [1] Group 1: Financial Performance - The company expects significant improvement in investment income and fair value changes from non-current financial assets, which include investments in non-listed companies, listed company shares, and pharmaceutical funds [1] - The anticipated net new orders for 2025 are projected to be between 9.5 billion and 10.5 billion yuan, compared to 8.42 billion yuan in the same period of 2024 [1] Group 2: Industry Context - The recovery of China's innovative pharmaceutical industry is expected to lead to a noticeable increase in the value of innovative assets within the sector [1]

报告期内，归属于上市公司股东的扣除非经常性损益后的净利润为人民币33,000万元至人民币49,000万 元，上年同期归属于上市公司股东的扣除非经常性损益后的净利润为人民币85,489.54万元，扣除非经常 性损益后的净利润与上年同期相比减少人民币36,489.54万元至人民币52,489.54万元，下降区间为 43%-61%。主要由于报告期内（1）公司有部分历史存量订单被取消，也有部分存量订单因客户资金问 题产生较为明显的回款压力，该等存量订单主要来自于国内依赖外部融资的初创型生物科技公司和部分 疫苗企业的与当前产业发展阶段不匹配的项目；存量订单的取消导致相关收入减少，相应地导致利润下 降；（2）随着行业需求的复苏和新签订单的增长，公司的临床运营、项目管理及业务拓展团队规模有 所增加，在日本等海外市场的团队规模也有所增加；同时，作为可持续性业务增长策略的一部分，公司 的数据管理和统计分析等业务在海外的团队规模有所增加，导致公司营业成本有所上升；（3）过去几 年，受上游行业周期和临床研究外包行业激烈竞争态势的影响，公司新签订单的平均单价有所下降，导 致公司2025年执行的订单单价同比有所下降，使得利润率有所下滑 ...

报告期内，归属于上市公司股东的非经常性损益为人民币50,000万元至人民币74,000万元；上年同期归 属于上市公司股东的非经常性损益为人民币-44,975.19万元，非经常性损益增加人民币94,975.19万元至 人民币118,975.19万元。 报告期内，公司持有的非流动金融资产（主要包括非上市公司股权投资、上市公司股份和医药基金）处 置及持有收益较上年同期大幅提升。2025年，随着中国创新药行业的复苏，产业内创新资产的价值也修 复明显；因此，公司持有的非流动金融资产产生的投资收益和公允价值变动损益同比大幅提升。此外， 公司也通过密切关注行业趋势及项目的融资、财务及研发状况等，定期实施风险筛查，识别潜在的风险 项目，并进行相应的公允价值调整。 证券之星消息，泰格医药发布业绩预告，预计2025年全年扣非后净利润盈利3.3亿元至4.9亿元。 公告中解释本次业绩变动的原因为： 报告期内，归属于上市公司股东的扣除非经常性损益后的净利润为人民币33,000万元至人民币49,000万 元，上年同期归属于上市公司股东的扣除非经常性损益后的净利润为人民币85,489.54万元，扣除非经常 性损益后的净利润与上年同期相比减 ...

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

泰格医药(300347.SZ)公告称，预计2025年归属于上市公司股东的净利润为8.30亿元–12.30亿元，比上年 同期增长105%–204%。业绩变动主要系报告期内非经常性损益大幅增加，公司持有的非流动金融资产 （包括非上市公司股权、上市公司股份及医药基金）处置及持有收益显著提升，叠加中国创新药行业复 苏带动资产价值修复。公司的新签订单数量和金额均较去年同期实现较好增长。2025年，公司净新增订 单（新签订单剔除取消订单后）区间为人民币95亿元至人民币105亿元，2024年同期净新增订单为人民 币84.20亿元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...